New research suggests that cholesterol boosts resistance in Helicobacter pylori both to many antibiotics and to the endogenous antimicrobial peptide, LL-37. A complete understanding of the pathway of cholesterol uptake might lead to novel strategies thwarting H. pylori by blocking that pathway, says corresponding author David McGee of Louisiana State University. The research is published in the June issue of the journal Antimicrobial Agents and Chemotherapy.
H. pylori infects one third of Americans, causing gastritis and peptic ulcers, and costing $10 billion annually. Antibiotic therapy is recommended, but resistance, often leading to treatment failures, is becoming increasingly common, even following the now-standard triple drug therapy.
In the study, the investigators grew H. pylori in the presence or absence of cholesterol, and treated the bacteria with different classes and concentrations of antibiotics, comparing the populations of surviving bacteria. "We found that H. pylori grown with cholesterol displayed a very dramatic increase in resistance to many antibiotics, bismuth, and to LL-37," says McGee.
"It would be important to learn whether we can manipulate the ability to clear H. pylori infections in animals and humans by lowering cholesterol either through dietary means or cholesterol-lowering drugs (statins)," says McGee. "There are already data showing that H. pylori-infected patients have elevated serum cholesterol levels, suggesting the bacteria manipulate the human host to produce more cholesterol." Additionally, he says, a study of 500 patients found that taking statins lowered the severity of chronic gastritis, which is also caused by H. pylori. But some statins work, and others don't, he says. And so far, no studies have combined antibiotics with statins. Thus, it is too soon to make recommendations to patients on their use to lower cholesterol, he says.
Interestingly, McGee says his research would not have been possible without the help of a high school student. Alika George, now an undergraduate at the University of Louisiana, collected some of the data, and urged McGee to include pepto bismol (bismuth) in the study, while taking part in a summer enrichment program for minority high school students, which was supported by Louisiana State University's Office of Multicultural Affairs. "I feel it is vital to be supportive of programs like this to give students opportunities they otherwise would not have had," says McGee.
Reference: D.J. McGee, A.E. George, E.A. Trainor, et al., 2011. Cholesterol enhances Helicobacter pylori resistance to antibiotics and LL-37. Antim. Agents Chemother. 55:2897-2904.
APIC Salutes 2025 Trailblazers in Infection Prevention and Control
June 18th 2025From a lifelong mentor to a rising star, the Association for Professionals in Infection Control and Epidemiology (APIC) honored leaders across the career spectrum at its 2025 Annual Conference in Phoenix, recognizing individuals who enhance patient safety through research, leadership, and daily practice.
Building Infection Prevention Capacity in the Middle East: A 7-Year Certification Success Story
June 17th 2025Despite rapid development, the Middle East faces a critical shortage of certified infection preventionists. A 7-year regional initiative has significantly boosted infection control capacity, increasing the number of certified professionals and elevating patient safety standards across health care settings.
Streamlined IFU Access Boosts Infection Control and Staff Efficiency
June 17th 2025A hospital-wide quality improvement project has transformed how staff access critical manufacturer instructions for use (IFUs), improving infection prevention compliance and saving time through a standardized, user-friendly digital system supported by unit-based training and interdepartmental collaboration.